Navigation Links
Cancer-killing compound spares healthy cells
Date:1/4/2012

This press release is available in French.

Montreal -- Lithocholic acid (LCA), naturally produced in the liver during digestion, has been seriously underestimated. A study published in the journal Oncotarget shows that LCA can kill several types of cancer cells, such as those found in some brain tumors and breast cancer.

The research team, led by Concordia University, included scientists from McGill University and the Jewish General Hospital's Lady Davis Institute in Montreal as well as the University of Saskatchewan.

Previous research from this same team showed LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could signal a huge improvement over the baby-with-the-bathwater drugs used in chemotherapy.

"LCA doesn't just kill individual cancer cells. It could also prevent the entire tumor from growing," says senior author Vladimir Titorenko, a professor in the Department of Biology and Concordia University Research Chair in Genomics, Cell Biology and Aging.

What's more, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Titorenko says LCA is the only compound that targets cancer cells, which could translate into tumor-halting power.

"This is important for preventing cancer cells from spreading to other parts of the body," he says, noting that unlike other anti-aging compounds, LCA stops cancer cell growth yet lets normal cells continue to grow.

A wide effect on different types of cancers

The next step for the research team will be to test LCA's effect on different cancers in mice models. Titorenko expects that LCA will also kill cancer cells in those experiments and lead to human clinical trials. "Our study found that LCA kills not only tumors (neuroblastomas), but also human breast cancer cells," says Titorenko. "This shows that it has a wide effect on different types of cancers."

Titorenko emphasizes that unlike drugs used in chemotherapy, LCA is a natural compound that is already present in our bodies. Studies have shown that LCA can be safely administered to mice by adding it to their food. So why is LCA so deadly for cancer cells? Titorenko speculates that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.

LCA sensors send signals to mitochondria the powerhouses of all cells. It seems that when these signals are too strong, mitochondria self-destruct and bring the cell down with them. Simply put, Titorenko and his colleagues engaged in cancer cell sabotage by targeting a weakness to LCA.


'/>"/>
Contact: Nadia Kherif
Nadia.Kherif@concordia.ca
514-848-2424 x4187
Concordia University
Source:Eurekalert

Related medicine news :

1. Cancer-killing cells are caught on film in more 3-D detail than ever before
2. Compound enhances cancer-killing properties of agent in trials
3. BUSM researchers identify novel compound to halt virus replication
4. Tumor-targeting compound points the way to new personalized cancer treatments
5. New compound defeats drug-resistant bacteria
6. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
7. Scripps Research scientists identify new class of antimalarial compounds
8. Compound found in common wart treatment shows promise as leukemia therapy
9. Mushroom compound appears to improve effectiveness of cancer drugs
10. Magic Mushroom Compound Triggered Positive Personality Change in Study
11. NYU researchers develop compound to block signaling of cancer-causing protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... Shark Finds and Kevin ... new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved ... who play in the wet and early morning dew or right after a rain shower, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, serving ... a new charity campaign. As part of their ongoing community involvement program, funds ... belief that children deserve a voice, and in the spirit of neighbors helping ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: